LeMaitre Vascular - LMAT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $50.00
  • Forecasted Upside: 7.71 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$46.42
▼ -0.09 (-0.19%)

This chart shows the closing price for LMAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LeMaitre Vascular Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LMAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LMAT

Analyst Price Target is $50.00
▲ +7.71% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for LeMaitre Vascular in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 7.71% upside from the last price of $46.42.

This chart shows the closing price for LMAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in LeMaitre Vascular. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/28/2022Barrington ResearchDowngradeOutperform ➝ Market PerformLow
4/29/2022Barrington ResearchLower Target$54.00 ➝ $50.00High
2/25/2022Barrington ResearchLower Target$62.00 ➝ $54.00Medium
9/16/2021Jefferies Financial GroupInitiated CoverageBuy$70.00Medium
8/3/2021Roth CapitalBoost TargetNeutral$55.00 ➝ $58.00High
7/30/2021Barrington ResearchBoost TargetOutperform$59.00 ➝ $64.00Low
5/4/2021Roth CapitalBoost TargetNeutral$53.00 ➝ $55.00Low
4/30/2021Lake Street CapitalBoost TargetBuy$55.00 ➝ $65.00High
4/30/2021Barrington ResearchBoost TargetMarket Perform ➝ Outperform$49.00 ➝ $59.00High
3/2/2021Roth CapitalReiterated RatingNeutralHigh
2/26/2021Barrington ResearchBoost TargetOutperform$47.00 ➝ $49.00Low
2/12/2021KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
10/30/2020Roth CapitalBoost TargetNeutral$32.00 ➝ $36.00High
10/30/2020Barrington ResearchBoost TargetOutperform$36.00 ➝ $46.00High
7/24/2020Stifel NicolausBoost TargetHold$25.00 ➝ $30.00High
7/24/2020Lake Street CapitalBoost TargetBuy$33.00 ➝ $38.00High
5/4/2020Stifel NicolausLower TargetHold$30.00 ➝ $25.00Medium
5/4/2020Roth CapitalLower TargetNeutral$32.50 ➝ $28.00High
5/1/2020Barrington ResearchLower TargetOutperform$38.00 ➝ $32.00High
4/8/2020SidotiLower TargetBuy$38.00 ➝ $34.00Low
4/6/2020Lake Street CapitalLower TargetBuy$40.00 ➝ $28.00High
3/16/2020SidotiUpgradeNeutral ➝ Buy$38.00High
2/24/2020Roth CapitalReiterated RatingNeutralLow
2/7/2020Barrington ResearchReiterated RatingBuy$38.00High
10/24/2019Lake Street CapitalUpgradeHold ➝ Buy$40.00High
10/24/2019First AnalysisDowngradeStrong-Buy ➝ Outperform$37.00 ➝ $40.00High
10/15/2019Barrington ResearchReiterated RatingOutperformMedium
10/14/2019First AnalysisUpgradeOutperform ➝ Strong-Buy$37.00High
7/25/2019Lake Street CapitalBoost TargetHold$27.00 ➝ $34.00High
7/25/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$32.00 ➝ $37.00High
7/25/2019First AnalysisUpgradeNeutral ➝ Outperform$29.00 ➝ $37.00High
5/2/2019Barrington ResearchReiterated RatingBuy$32.00High
2/21/2019Roth CapitalReiterated RatingNeutralLow
2/20/2019Lake Street CapitalBoost TargetHold$27.00High
1/23/2019Lake Street CapitalReiterated RatingHold$24.00Medium
10/8/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$34.00High
10/8/2018Roth CapitalUpgradeNeutral ➝ Buy$39.00 ➝ $34.00High
10/5/2018Lake Street CapitalDowngradeBuy ➝ HoldHigh
10/2/2018Roth CapitalDowngradeBuy ➝ Neutral$38.00 ➝ $39.00Low
6/25/2018Lake Street CapitalInitiated CoverageBuy$45.00Low
6/8/2018Roth CapitalInitiated CoverageBuy$38.00High
4/26/2018BenchmarkUpgradeHold ➝ Buy$40.00High
4/26/2018Stifel NicolausDowngradeBuy ➝ Hold$40.00 ➝ $34.00High
(Data available from 12/10/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/13/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/12/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/12/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/9/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/9/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
LeMaitre Vascular logo
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $46.42
Low: $46.28
High: $47.15

50 Day Range

MA: $47.02
Low: $41.94
High: $52.25

52 Week Range

Now: $46.42
Low: $38.32
High: $56.38

Volume

54,836 shs

Average Volume

105,351 shs

Market Capitalization

$1.02 billion

P/E Ratio

48.35

Dividend Yield

1.08%

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of LeMaitre Vascular?

The following sell-side analysts have issued stock ratings on LeMaitre Vascular in the last twelve months: Barrington Research, and StockNews.com.
View the latest analyst ratings for LMAT.

What is the current price target for LeMaitre Vascular?

1 Wall Street analysts have set twelve-month price targets for LeMaitre Vascular in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 7.7%. Barrington Research has the highest price target set, predicting LMAT will reach $50.00 in the next twelve months. Barrington Research has the lowest price target set, forecasting a price of $50.00 for LeMaitre Vascular in the next year.
View the latest price targets for LMAT.

What is the current consensus analyst rating for LeMaitre Vascular?

LeMaitre Vascular currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LMAT, but not buy more shares or sell existing shares.
View the latest ratings for LMAT.

What other companies compete with LeMaitre Vascular?

How do I contact LeMaitre Vascular's investor relations team?

LeMaitre Vascular's physical mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier's listed phone number is (781) 221-2266. The official website for LeMaitre Vascular is www.lemaitre.com. Learn More about contacing LeMaitre Vascular investor relations.